Axonal target-derived BMP and neurotrophin signaling are both known to regulate neuronal gene expression, differentiation, and axon growth. In this issue of Neuron, Ji and Jaffrey (2012) discovered that BMP-signaling endosomes depend on BDNF-induced axonal synthesis of SMADs to retrogradely regulate transcription in developing trigeminal neurons, providing a mechanism of integrating the two target-derived signals.
During nervous system development, axonal target-derived signals can induce transcriptional changes which are essential for neuronal differentiation and correct assembly of neural circuits. The rodent trigeminal sensory system has served as an excellent model to study such processes. Cutaneous sensory information from three distinct facial regions is transmitted to the brain by the three branches of the trigeminal ganglion: ophthalmic (Op), maxillary (Mx), and mandibular (Md) branches ( Figure 1A) . A number of facial target-derived signals have been shown to regulate different aspects of the specification, peripheral axon growth, central axon projection, and survival of developing trigeminal sensory neurons (Davies, 1997; O'Connor and Tessier-Lavigne, 1999; Hodge et al., 2007; da Silva et al., 2011) . Two factors in particular, brain-derived neurotrophic factor (BDNF) and bone morphogenic protein 4 (BMP4), have been the focus of recent study, including a paper in this issue of Neuron from Ji and Jaffrey (2012) . In early embryonic development, between embryonic days E10 and E12, BDNF is expressed by both the ophthalmic and maxillary targets as well as the corresponding pathway mesenchyme, and it serves as one of the ''chemoattractants'' that attract the axon outgrowth of trigeminal peripheral axons ( Figure 1A ; O'Connor and TessierLavigne, 1999) . After initial axon extension, BMP4, which is also selectively expressed by epidermis in the ophthalmic and maxillary regions at these stages, retrogradely signals to trigeminal neurons and induces spatially patterned expressions of several transcription factors along the dorsoventral axis of the trigeminal ganglion (Hodge et al., 2007) . One such BMP4-retrograde signaling induced gene is Tbx3 ( Figure 1A) .
The intracellular mechanisms that mediate this BMP4-retrograde signal in trigeminal neurons have been unclear. Ji and Jaffrey (2012) describe an interesting union between BDNF-induced axonal translation of SMADs (which are effectors carrying out the BMP transcriptional signaling) and axon-derived BMP4-signaling endosomes that together mediate the retrograde specification of trigeminal neurons (summarized in Figure 1B ).
Using microfluidic chambers for compartmentalized cultures and separate manipulations of trigeminal neuron cell bodies versus axons, the authors established that adding BMP4 to the axons resulted in the appearance of phosphorylated-SMAD1/5/8 (pSMADs) within 15 min and Tbx3 gene transcription within 4 hr in the neuronal cell bodies. To show that BMP4 retrograde signaling endosomes were required for this process, they applied biotinylated-BMP4 to the axons and subsequently found the endocytosed BMP4 within cell bodies. Both the retrograde transport of BMP4 and the downstream signaling (as assayed by pSMADs and Tbx3) were blocked by a dynein (the retrograde motor protein) inhibitor. Furthermore, adding BMPreceptor kinase inhibitors selectively to the cell body compartment prevented retrograde signaling by BMP4 applied to the axons. This result suggested that activated BMP-receptors, presumably those residing on the axon-derived endosomes with internalized BMP4, are required at the neuronal cell bodies for eliciting downstream signal transduction ( Figure 1B , growth cone and cell body panel).
The authors next sought to identify the sources of SMADs. Previous studies have shown that phosphorylated SMAD proteins are present in trigeminal axons contacting BMP4-expressing targets (Hodge et al., 2007) . Ji and Jaffrey (2012) also showed that their mRNAs could be localized in axons both in culture and in vivo ( Figure 1B , middle panel), leading to the question of whether the axonal SMAD proteins were derived from intraaxonal translations of the corresponding mRNAs. Several lines of evidence indicated that this was indeed the case. Protein synthesis blockers applied to the axon chamber resulted in the depletion of SMAD proteins in axons, as the axonal SMADs were constitutively transported back to cell bodies by a dynein-based mechanism ( Figure 1B, middle panel) . When a Dendra2-SMAD1 (with 3 0 UTR of Smad1) construct was expressed in cultured trigeminal neurons, photoconversion of Dendra2-SMAD1 fusion protein located at the cell bodies showed that photo-converted proteins did not diffuse into axons; thus, there was minimum anterograde transport of SMADs to the axons. Further, the authors showed that when the axons were severed from their cell bodies and then photo-bleached, the fluorescence recovered within 10 min, which could only occur if the new fluorescent protein was synthesized locally within the cut axons.
Ji and Jaffrey (2012) went on to show that BMP retrograde signaling required axonally synthesized SMADs. Either blocking axonal protein synthesis with inhibitors or applying a siRNA cocktail against SMAD1/5/8 selectively to axon chambers diminished retrograde induction of Tbx3 and pSMADs in cell bodies by BMP4. How might the axonal synthesis of SMADs proteins be regulated? The authors noticed that in vivo, SMADs proteins were present in the ophthalmic and maxillary but not the mandibular branches of trigeminal nerves, despite the fact that SMADs mRNAs were observed in all branches. BDNF was previously known to be highly expressed along the pathways and in the targets of the ophthalmic and maxillary branches, but not of the mandibular branch ( Figure 1A ; O'Connor and TessierLavigne, 1999) . A clue to the how the BDNF data may relate to regulation of SMAD protein expression came from the observation that BDNF itself could be used to induce SMADs protein translation in isolated axons in culture and that this effect was local, not requiring retrograde Trk signaling ( Figure 1B , right panel). Likewise, in BDNF null mutant embryos, which were known to have normal initial axon outgrowth at stages E10-E11.5 (O'Connor and TessierLavigne, 1999), there were significantly reduced axonal SMADs, decreased nuclear pSMADs, and diminished Tbx3 expression in trigeminal sensory neurons of the Op and Mx divisions. These findings provided in vivo evidence that targetderived BDNF is critical for the translation of SMADs in axons and for BMP4-retrograde signaling in developing trigeminal neurons. It is also worth noting that the authors performed multiple control experiments, including those that showed protein synthesis inhibitors, Trk-kinase inhibitor, as well as siRNA applied to axons did not affect axonal transport.
The interesting findings presented in this paper also raise several questions. Why would axonal translation of SMAD proteins be needed in the first place when there are SMADs produced at the cell body? The BMP-signaling endosomes are retrogradely transported back to the cell body, so shouldn't the receptors on the endosomes be able to phosphorylate the cell body derived SMADs and induce downstream transcriptional changes just as well? One possible explanation offered by the authors is that perhaps activated receptors are more efficient at recruiting SMADs located in the vicinity during endocytosis through adaptor proteins (Moustakas and Heldin, 2009) , although this idea was not tested. On the other hand, it is not inconceivable that axons synthesize more SMAD proteins than is possible in the cell bodies. Considering that the diameter of an embryonic trigeminal sensory neuron is about 10 mm with a large nucleus of 89 mm in diameter, this makes the net cytoplasm of the cell body roughly 1,600 mm 3 . At E11.5, the trigeminal axons have grown roughly 1,000 mm in length, and with a diameter of 1 mm, the volume of the axonal cytoplasm is about 3,000 mm 3 . The growth cones vary in size, but many are larger than the cell body. Thus, together, the total volume of cytoplasm in axon and growth cone can be significantly larger than that of cell body, potentially containing more materials for protein synthesis. Although the number of ribosomes in axons is fewer than that in cell bodies, at the same time, only selected mRNAs species are located in axons. It is also possible that the axonal ribosomes may be dedicated to translate only select proteins and could therefore potentially synthesize more of particular SMADs than does the cell body. The anti-SMAD immunofluorescence staining results in this and previous studies (Ji and Jaffrey, 2012; Hodge et al., 2007) showed that the axons of trigeminal neurons in the ophthalmic and maxillary branches showed strong signal (and hence high concentrations of SMADs) all along the axon. These axonal SMADs are constantly and rapidly transported back to cell bodies. Depleting this major source of SMAD synthesis could thus severely reduce the total amount of SMADs, thereby hindering BMP signaling. Another related question is if SMADs are phosphorylated within the axons and are trafficked back to cell bodies, why is there a need for BMP-signaling endosomes to be present in cell bodies. Perhaps pSMADs are labile and there are many negative regulatory mechanisms at the cell body that could lead to either rapid degradation or inactivation of pSMADs (Moustakas and Heldin, 2009) , and thus a persistent source of activated BMP receptors is needed for sustaining the retrograde signaling. As to the BDNF-induced axonal translation of SMAD mRNAs, it would be interesting to examine whether the induction mechanism in trigeminal axons is similar to what has been shown for BDNF-induced translation in dendrites/synapses, which occurs primarily through activating the mTOR pathway to modulate translation initiation and elongation (Santos et al., 2010) .
There are also some outstanding general questions. For example, how are mRNAs and ribosomes transported into axons? It is generally believed that mRNAs are delivered to dendrites and axons in ''granules'' (Kiebler and Bassell, 2006) . Large granules may contain ribosome subunits (Sossin and DesGroseillers, 2006) . However, it is unclear whether all mRNAs are transported by granules. Studies in nonneuronal cells have found that a large populations of mRNAs encoding cytosolic (nonsecretory, nonmembrane) proteins are localized to the endoplasmic reticulum (ER) (Pyhtila et al., 2008) . In other words, there are signal-sequence-independent mechanisms that direct mRNA localizations to the ER. Since the ER permeates the entire neuron including the axonal processes, some mRNAs could be simply carried by the ER into axons ( Figure 1B) .
Accumulating evidence has shown that axons of nonmammalian neurons and embryonic mammalian neurons have the capacity to synthesize proteins, and in vivo in the adult mouse, ribosomes could be transferred from Schwann cells to the injured distal axons of the peripheral nerve (Twiss and Fainzilber, 2009 , and the references therein). Nevertheless, ribosomes were rarely observed in axons of mature central nervous system neurons in mammals, although they could be found in the axon hillock (Steward, 1997) . The cellular mechanisms that prevent ribosomes from entering into the axons of mature neurons remain unclear, although it is conceivable that in immature growing neurons, ribosomes may move into axons as part of the vectorial flow of cytoplasm (Bradke and Dotti, 1997) . Perhaps as the neurons mature and become polarized, their axon initial segment (AIS) is established and the AIS serves as a selective cytoplasmic ''filter'' (Song et al., 2009 ) that excludes ribosomes from getting into axons. This possibility could, in principle, be examined in mature neurons in which the AIS is acutely disrupted by conditional deletion of the specific ankyrin G isoform (Grubb and Burrone, 2010) .
Finally, it will also be interesting to examine whether this mechanism of integrating two major types of target-derived signals, i.e., neurotrophic factors stimulating the axonal synthesis of SMADs and TGFb-superfamily factors forming retrograde signaling endosomes, is used elsewhere in the nervous system for retrograde specification of neuronal subtype identities.
